For research use only. We do not sell to patients.
Research lipid catalog

Ionizable Lipid Products

Explore 848 lipid and RNA delivery products. Search the full catalog or browse by research category.

Search covers product name, catalog number, synonyms, available CAS numbers and categories. Spaces, hyphens and common punctuation are ignored. Duplicate legacy records are consolidated under one canonical product result.

3666 products · Showing 2861–2880 · 20 per page
DC Chemicals lipid expertise

Built for ionizable-lipid discovery and RNA delivery research

DC Chemicals supports formulation and delivery research with a broad, searchable portfolio of cationic and ionizable lipids. The current directory brings together 848 unique research-use products, with product specifications, pricing, chemical structures and literature-linked formulation data added as each record is verified.

Our experience spans complex lipid synthesis, purification, analytical release and process development. For custom molecules or larger-scale requirements, our team can discuss route development, technical specifications and scale-up options for the intended research workflow.

Learn about cationic and ionizable lipids →
848unique products in the current searchable directory
Evidence-awareliterature modules appear only after source review
Research supportformulation context, handling guidance and calculators
Proprietary innovation · Co-development · GMP

From proprietary lipid design to GMP-grade custom synthesis

DC Chemicals has independently developed ionizable-lipid structures supported by company-owned intellectual property, and selected proprietary lipid programs have advanced to GMP-stage development.

We welcome joint development with customers—from molecular design and lipid synthesis through route and process development. We can also support custom synthesis of GMP-grade ionizable lipids to agreed technical specifications and quality requirements.

Discuss a co-development project →
Proprietary ionizable-lipid structuresCollaborative molecular designCustom lipid synthesisProcess development and scale-upGMP-grade project support

Cat. No.Product NameField of ApplicationChemical Structure
100mg USD 450 · 10 mM * 1 mL in DMSO USD 220 · 250mg USD 800 · 1g USD 1,600

PLX5622 hemifumarate is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 µM; Ki=5.9 nM). PLX5622 hemifumarate allows for extended and specific microglial elimination, preceding and during pathology development. PLX5622 hemifumarate demonstrates desirable PK properties in varies animals.

PLX5622 hemifumarate chemical structure
100 mg USD 500 · 250 mg USD 1,000 · 1 g USD 1,800 · 10 mM * 1 mL in DMSO USD 220

AC480 (BMS-599626) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, >100-fold to VEGFR2, c-Kit, Lck, MET etc

BMS-599626 (AC480) chemical structure
100 mg USD 550 · 250 mg USD 1,000 · 1 g USD 1,900 · 10 mM * 1 mL in DMSO USD 220

GSK-J4 is a potent H3K27me3 histone lysine demethylase (KDM) inhibitor, with IC50s of 8.6 μM and 6.6 μM against KDM6B and KDM6A, respectively.

GSK-J4 hydrochloride chemical structure
SW033291Featured
100 mg USD 450 · 250 mg USD 800 · 1 g USD 1,600 · 10 mM * 1 mL in DMSO USD 220

SW033291 is a small-molecule inhibitor of 15-PGDH (Ki=0.1 nM) that increases prostaglandin PGE2 levels in bone marrow and other tissues.

SW033291 chemical structure
MRT67307 HClFeatured
100 mg USD 450 · 250 mg USD 900 · 1 g USD 1,800 · 10 mM * 1 mL in DMSO USD 220

MRT67307 is a dual inhibitor of the IKKε and TBK-1 with IC50s of 160 and 19 nM, respectively. MRT67307 also inhibits ULK1 and ULK2 with IC50s of 45 and 38 nM, respectively.

MRT67307 HCl chemical structure
100 mg USD 450 · 250 mg USD 900 · 1 g USD 1,800 · 10 mM * 1 mL in DMSO USD 220

Ulixertinib (VRT752271) is a reversible, ATP-competitive inhibitor of ERK1 and ERK2 kinases, with IC50 of <0.3 nM against ERK2.

Ulixertinib (BVD-523, VRT752271) chemical structure
WAY-200070Featured
100 mg USD 350 · 250 mg USD 550 · 1 g USD 1,100 · 10 mM * 1 mL in DMSO USD 150

WAY-200070 is a selective estrogen receptor β (ERRβ) agonist with an IC50 of 2.3 nM.

WAY-200070 chemical structure
CP 376395Featured
100 mg USD 400 · 250 mg USD 700 · 1 g USD 1,400 · 10 mM * 1 mL in DMSO USD 150

CP 376395 is a potent and selective Corticotropin releasing factor 1 (CRF1) receptor antagonist.

CP 376395 chemical structure
100 mg USD 350 · 250 mg USD 700 · 1 g USD 1,400 · 10 mM * 1 mL in DMSO USD 150

Trifluridine-tipiracil hydrochloride mixture (TAS-102) is a novel oral combination drug that consists of an antineoplastic thymidine-based nucleoside analog, trifluorothymidine, and a potent thymidine phosphorylase inhibitor, tipiracil, in a 1:0.5 molar ratio.

TAS-102 (Trifluridine/tipiracil hydrochloride, 2:1) chemical structure
SRT1720 HClFeatured
100 mg USD 350 · 250 mg USD 650 · 1 g USD 1,200 · 10 mM * 1 mL in DMSO USD 150

SRT 1720 Hydrochloride is a selective activator of SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities on SIRT2 and SIRT3 with EC1.5s of 37 μM and 300 μM, respectively.

SRT1720 HCl chemical structure
100 mg USD 625 · 250 mg USD 1,250 · 1 g USD 2,500 · 10 mM * 1 mL in DMSO USD 220

Siramesine(Lu 28-179) Hcl is a selective sigma-2 receptor agonist, which has been shown to trigger cell death of cancer cells and to exhibit a potent anticancer activity in vivo.lysosome-destabilizing agentsiramesine can induce rapid cell death in a number of cell lines at concentrations above 20 μM. In HaCaT cells, cell death was accompanied by caspase activation, rapid loss of mitochondrial membrane potential (MMP), cytochrome c release, cardiolipin peroxidation and typical apoptotic morphology, whereas in U-87MG cells most apoptotic hallmarks were not notable, although MMP was rapidly lost [1]. Siramesine, a sigma-2 receptor agonist originally developed as an anti-depressant, can induce cell death in transformed cells through a mechanism involving lysosomal destabilization [2].

Siramesine-hydrochloride chemical structure
BRD7552Featured
100 mg USD 600 · 250 mg USD 1,100 · 1 g USD 2,200 · 10 mM * 1 mL in DMSO USD 220

BRD7552 is an inducer of transcription factor PDX1, which increases insulin expression.

BRD7552 chemical structure
AVN944Featured
100 mg USD 700 · 250 mg USD 1,400 · 1 g USD 2,700 · 10 mM * 1 mL in DMSO USD 220

AVN-944(VX-944) is a selective, noncompetitive inhibitor of the enzyme directed against human IMPDH with Ki of 6-10 nM for IMPDH1/IMPDH2

AVN944 chemical structure
100 mg USD 500 · 250 mg USD 1,000 · 1 g USD 2,000 · 10 mM * 1 mL in DMSO USD 220

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM; shows 30-fold greater selectivity against PLK2 and no activity to PLK3.

Rigosertib sodium chemical structure
SB-269970Featured
100 mg USD 700 · 250 mg USD 1,300 · 1 g USD 2,700 · 10 mM * 1 mL in DMSO USD 220

SB269970 is a 5-HT7 receptor antagonist with pKi of 8.3, exhibits >50-fold selectivity against other receptors.

SB-269970 chemical structure
C646Featured
100 mg USD 450 · 250 mg USD 800 · 1 g USD 1,500 · 10 mM * 1 mL in DMSO USD 220

C646 is a selective and competitive histone acetyltransferase p300 inhibitor with Ki of 400 nM, and is less potent for other acetyltransferases.

C646 chemical structure
100 mg USD 750 · 250 mg USD 1,500 · 1 g USD 3,000 · 10 mM * 1 mL in DMSO USD 220

Miglustat hydrochloride is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).Miglustat is an inhibitor of the ceramide-specific glycosyltransferase, which catalyzes the first step of glycosphingolipid biosynthesis and is currently approved for the oral treatment of type 1 GD [1]. Consumption of a standard high-fat breakfast within 30 minutes before administration of miglustat significantly reduced peak exposure but did not significantly affect the extent of systemic exposure to miglustat. The peak plasma concentration (C(max)) decreased by 36% on average following administration with food. Area under the plasma concentration-time curve (AUC(0-infinity)) showed a modest (14%) decrease with food, but the 90% confidence interval was within the acceptance limit of 80% to 125%. The median (min-max) time to C(max) (t(max)) was prolonged from 2.5 (1.0-4.0) hours in the fasted state to 4.5 (1.5-8.0) hours in the fed state, whereas the apparent terminal half-life was approximately 8 hours and not affected by food [2].

Miglustat hydrochloride chemical structure
1g USD 2,200 · 100 mg USD 600 · 250 mg USD 1,100 · 10 mM * 1 mL in DMSO USD 220

Tyk2-IN-4 is a selective, potent, allosteric inhibitor of tyrosine kinase 2 (Tyk2).

Deucravacitinib (BMS-986165) chemical structure
10 mg USD 450

Migalastat hydrochloride (1-Deoxygalactonojirimycin hydrochloride) is a potent and competitive inhibitor of α-galactosidase A (α-Gal A) with an IC50 of 0.04 μM for human α-Gal A.

Migalastat hydrochloride chemical structure
FIN56Featured
100 mg USD 450 · 250 mg USD 800 · 1 g USD 1,600 · 10 mM * 1 mL in DMSO USD 220

FIN56 is a specific inducer of ferroptosis.

FIN56 chemical structure

Page 144 of 184 · Browse all 3666 products

Jump to a product page